Market Overview

Bone Biologics Completes $5.9 Million of Financing


Bone Biologics (OTCQB:BBLG), a developer
of orthobiologic products for domestic and international spine fusion
markets, announced today the completion of $5.9 million funding; $3.9
million in equity and a $2 million credit facility. Proceeds will be
used for working capital, protein development, animal testing,
regulatory and clinical expenses, as well as for other purposes not
presently contemplated herein but which are related directly to growing
the Company's current business, research and development activities and
the repayment of a secured promissory note in the principal amount of

The securities offered have not been registered under the Securities Act
of 1933, as amended, and may not be offered or sold in the United States
absent registration or an applicable exemption from the registration
requirements of the Securities Act and applicable state securities laws.

About Bone Biologics

Bone Biologics (OTCQB:BBLG) was founded to pursue regenerative medicine
for bone.

Bone Biologics Corporation is undertaking groundbreaking work with
select strategic partners, building on unprecedented research on the
Nell-1 molecule that has produced a significant number of studies and
publications in peer reviewed scientific literature.

Bone Biologics is currently focusing its development efforts for its
bone graft substitute product on bone regeneration in spinal fusion and
has rights to trauma and osteoporosis applications. Nell-1 is a
recombinant human protein growth factor that is essential for normal
bone development.

For more information, please visit the company's website at

Bone Biologics trades on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies. OTCQB companies
are current in their reporting and undergo an annual verification and
management certification process. Investors can find Real-Time quotes
and market information for the company on

Forward-Looking Statements

This press release contains forward-looking statements that reflect the
Company's current beliefs, expectations or intentions regarding future
events. Any statements contained in this press release that are not
statements of historical fact may be deemed forward-looking statements.
Words such as "will," "will be," "anticipate," "predict," "continue,"
"future," and similar expressions are intended to identify such
forward-looking statements.


This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any
sale of securities in any jurisdiction in which the offer, solicitation
or sale would be unlawful prior to the registration or qualification
under the securities laws of any such jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as amended.

View Comments and Join the Discussion!